{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:02:33Z","timestamp":1790827353738,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary carcinomas are aggressive cancers with a high mortality rate. When metastatic, biliary cancers are associated with a short survival and low response to treatments. The first line therapy of metastatic biliary carcinomas consists of a platinum doublet chemotherapy combination with an immune checkpoint inhibitor and results in a median overall survival in the range of approximately 12\u201313 months, with 20% to 25% of patients surviving at 2 years. Second line chemotherapy options based on fluoropyrimidines are associated with a median survival of less than 6 months. Genomic studies in recent years have clarified molecular aspects of biliary cancers and have confirmed the molecular heterogeneity between the intrahepatic, extrahepatic and gallbladder primary sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publicly available genomic cohorts of biliary cancer primary locations were interrogated for common mutations and copy number alterations with a focus on receptor tyrosine kinases and their signal transduction pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Specific mutations and structural alterations have different prevalence depending on the primary location. Alterations in receptor tyrosine kinases and the transduction pathways originating from them show differential prevalence in the primary locations of the biliary cancers and create diverse treatment opportunities that can be harnessed for drug development. Approximately 49% of intrahepatic, 57.6% of gallbladder, and 66% of extrahepatic carcinomas harbor RTK pathway alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted therapies for individual components of these kinase receptors and pathways, including FGFR2, HER2, BRAF and others, have already been introduced in clinical practice for the treatment of patients with biliary tumors bearing alterations in these genes. The findings underscore the need for primary site-driven genomic testing to guide therapy selection. The current analysis discusses strategies to create opportunities for clinically available targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-025-01335-4","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:49:08Z","timestamp":1760816948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Landscape of Genomic Alterations in Receptor Tyrosine Kinase Pathways in Biliary Cancers: Implications for Targeted Therapies"],"prefix":"10.1007","volume":"56","author":[{"given":"Ioannis A.","family":"Voutsadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"issue":"3","key":"1335_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41416-024-02692-w","volume":"131","author":"BA Uijterwijk","year":"2024","unstructured":"Uijterwijk BA, Lemmers DH, Ghidini M, Wilmink JW, Zaniboni A, Fusai GK, et al. The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: an international multimethod cohort study. Br J Cancer. 2024;131(1):117\u201325. https:\/\/doi.org\/10.1038\/s41416-024-02692-w.","journal-title":"Br J Cancer"},{"issue":"1","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/curroncol30010030","volume":"30","author":"N Guedj","year":"2022","unstructured":"Guedj N. Pathology of cholangiocarcinomas. Curr Oncol. 2022;30(1):370\u201380. https:\/\/doi.org\/10.3390\/curroncol30010030.","journal-title":"Curr Oncol"},{"issue":"Suppl 1","key":"1335_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331. https:\/\/doi.org\/10.1111\/liv.14095.","journal-title":"Liver Int"},{"issue":"4","key":"1335_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jhep.2020.04.046.PMID:32437829;PMCID:PMC7901003","volume":"73","author":"SS Jackson","year":"2020","unstructured":"Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, de Gonz\u00e1lez AB, Buring JE, et al. Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. J Hepatol. 2020;73(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.046.PMID:32437829;PMCID:PMC7901003.","journal-title":"J Hepatol"},{"issue":"7","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/ijc.35232","volume":"156","author":"M Pi\u00f1eros","year":"2025","unstructured":"Pi\u00f1eros M, Vignat J, Colombet M, Laversanne M, Ferreccio C, Heise K, et al. Global variations in gallbladder cancer incidence: what do recorded data and national estimates tell us? Int J Cancer. 2025;156(7):1358\u201368. https:\/\/doi.org\/10.1002\/ijc.35232.","journal-title":"Int J Cancer"},{"issue":"11","key":"1335_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115780","volume":"22","author":"Y Takahashi","year":"2021","unstructured":"Takahashi Y, Dungubat E, Kusano H, Ganbat D, Tomita Y, Odgerel S, et al. Application of immunohistochemistry in the pathological diagnosis of liver tumors. Int J Mol Sci. 2021;22(11):5780. https:\/\/doi.org\/10.3390\/ijms22115780.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1335_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN guidelines\u00ae insights: biliary tract cancers, version 2.2023. J Natl Compr Canc Netw. 2023;21(7):694\u2013704. https:\/\/doi.org\/10.6004\/jnccn.2023.0035.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver, European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"issue":"3","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology. 2021;74(3):1429\u201344. https:\/\/doi.org\/10.1002\/hep.31829.","journal-title":"Hepatology"},{"issue":"24","key":"1335_CR11","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-22-1954","volume":"28","author":"NA Giraldo","year":"2022","unstructured":"Giraldo NA, Drill E, Satravada BA, Dika IE, Brannon AR, Dermawan J, et al. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022;28(24):5359\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1954.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1335_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151.PMID:28572459;PMCID:PMC5611790","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","unstructured":"AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0151.PMID:28572459;PMCID:PMC5611790.","journal-title":"Cancer Discov"},{"issue":"5","key":"1335_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"issue":"269","key":"1335_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"issue":"1","key":"1335_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 2024;14(1):49\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0467.","journal-title":"Cancer Discov"},{"key":"1335_CR16","doi-asserted-by":"publisher","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017; 2017: PO.17.00011. https:\/\/doi.org\/10.1200\/PO.17.00011. PMID: 28890946; PMCID: PMC5586540.","DOI":"10.1200\/PO.17.00011"},{"issue":"1","key":"1335_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"key":"1335_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf155","author":"M Rimini","year":"2025","unstructured":"Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, et al. The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population. J Natl Cancer Inst. 2025. https:\/\/doi.org\/10.1093\/jnci\/djaf155.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1335_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00408-6","volume":"7","author":"TG Chang","year":"2023","unstructured":"Chang TG, Cao Y, Shulman ED, Ben-David U, Sch\u00e4ffer AA, Ruppin E. Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations. NPJ Precis Oncol. 2023;7(1):54. https:\/\/doi.org\/10.1038\/s41698-023-00408-6.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1335_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08794-5","volume":"21","author":"M T\u00f3th","year":"2021","unstructured":"T\u00f3th M, Wehling L, Thiess L, Rose F, Schmitt J, Weiler SME, et al. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer. 2021;21(1):1079. https:\/\/doi.org\/10.1186\/s12885-021-08794-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"1335_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10637-023-01394-z","volume":"42","author":"C Zhang","year":"2024","unstructured":"Zhang C, You X, Zhang Q, Wang D. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study. Invest New Drugs. 2024;42(1):24\u201334. https:\/\/doi.org\/10.1007\/s10637-023-01394-z.","journal-title":"Invest New Drugs"},{"issue":"17","key":"1335_CR22","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0078.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1335_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","volume":"10","author":"A Vogel","year":"2025","unstructured":"Vogel A, Ducreux M. Esmo clinical practice guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104003.","journal-title":"ESMO Open"},{"issue":"10","key":"1335_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(21)00196-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1335_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1335_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"key":"1335_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejca.2022.02.013","volume":"166","author":"M Rizzato","year":"2022","unstructured":"Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, et al. Prognostic impact of FGFR2\/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. Eur J Cancer. 2022;166:165\u201375. https:\/\/doi.org\/10.1016\/j.ejca.2022.02.013.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1335_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","volume":"80","author":"TP DiPeri","year":"2024","unstructured":"DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, et al. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024;80(2):322\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.041.","journal-title":"J Hepatol"},{"issue":"3","key":"1335_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19(3):847\u201357. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0631.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1335_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","volume":"36","author":"L Goyal","year":"2025","unstructured":"Goyal L, DiToro D, Facchinetti F, Martin EE, Peng P, Baiev I, et al. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann Oncol. 2025;36(4):426\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.011.","journal-title":"Ann Oncol"},{"issue":"30","key":"1335_CR31","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2217\/fon-2020-0429","volume":"16","author":"TS Bekaii-Saab","year":"2020","unstructured":"Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020;16(30):2385\u201399. https:\/\/doi.org\/10.2217\/fon-2020-0429.","journal-title":"Future Oncol"},{"issue":"23","key":"1335_CR32","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-23-1926","volume":"29","author":"TY Tang","year":"2023","unstructured":"Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, et al. Comparative genomic analysis and clinical outcomes of BRAF-mutated advanced biliary tract cancers. Clin Cancer Res. 2023;29(23):4853\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1926.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1335_CR33","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(20)30321-1.","journal-title":"Lancet Oncol"},{"issue":"33","key":"1335_CR34","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AKS Salama","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol h. J Clin Oncol. 2020;38(33):3895\u2013904. https:\/\/doi.org\/10.1200\/JCO.20.00762.","journal-title":"J Clin Oncol"},{"key":"1335_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102447","volume":"69","author":"T Shimoi","year":"2024","unstructured":"Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, et al. Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. eClinicalMedicine. 2024;69:102447. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102447.","journal-title":"eClinicalMedicine"},{"issue":"3","key":"1335_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB. BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol. 2024;21(3):224\u201347. https:\/\/doi.org\/10.1038\/s41571-023-00852-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1335_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.23.01193","volume":"42","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Mandavkar S, Bhargava P, Srinivas S, Kapoor A, Shetty O, et al. Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J Clin Oncol. 2024;42(7):800\u20137. https:\/\/doi.org\/10.1200\/JCO.23.01193.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1335_CR38","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol. 2024;42(27):3207\u201317. https:\/\/doi.org\/10.1200\/JCO.23.02010.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1335_CR39","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1200\/JCO.23.02078","volume":"42","author":"TL Cannon","year":"2024","unstructured":"Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, et al. Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: results from the targeted agent and profiling utilization registry study. J Clin Oncol. 2024;42(27):3228\u201337. https:\/\/doi.org\/10.1200\/JCO.23.02078.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1335_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2023;8(1):56\u201365. https:\/\/doi.org\/10.1016\/S2468-1253(22)00335-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"36","key":"1335_CR41","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J Clin Oncol. 2023;41(36):5569\u201378. https:\/\/doi.org\/10.1200\/JCO.23.00606.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1335_CR42","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical claridhy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"issue":"10391","key":"1335_CR43","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"8","key":"1335_CR44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"1335_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Engl J Med Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"N Engl J Med Evid"},{"issue":"1","key":"1335_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280348","volume":"18","author":"R Tanaka","year":"2023","unstructured":"Tanaka R, Eguchi S, Kimura K, Ohira G, Tanaka S, Amano R, et al. Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer. PLoS ONE. 2023;18(1):e0280348. https:\/\/doi.org\/10.1371\/journal.pone.0280348.","journal-title":"PLoS ONE"},{"issue":"20","key":"1335_CR47","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1158\/1078-0432.CCR-24-1265","volume":"30","author":"YH Bang","year":"2024","unstructured":"Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer. Clin Cancer Res. 2024;30(20):4635\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1265.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1335_CR48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1335_CR49","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","volume":"9","author":"J Hyung","year":"2023","unstructured":"Hyung J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, et al. Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b nifty randomized clinical trial. JAMA Oncol. 2023;9(5):692\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0016.","journal-title":"JAMA Oncol"},{"key":"1335_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100055","volume":"4","author":"A Digklia","year":"2024","unstructured":"Digklia A, Arnold D, Voutsadakis IA. Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin\/gemcitabine: a systematic review and meta-analysis. ESMO Gastrointestinal Oncology. 2024;4:100055.","journal-title":"ESMO Gastrointestinal Oncology"},{"issue":"4","key":"1335_CR51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.clcc.2024.05.009","volume":"23","author":"IA Voutsadakis","year":"2024","unstructured":"Voutsadakis IA, Kokkali S, Digklia A. Treatment of metastatic biliary cancers with irinotecan and 5-fluorouracil based chemotherapy after platinum\/gemcitabine progression: a systematic review and meta-analysis. Clin Colorectal Cancer. 2024;23(4):318-325.e1. https:\/\/doi.org\/10.1016\/j.clcc.2024.05.009.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1335_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cncr.29778","volume":"122","author":"F Leone","year":"2016","unstructured":"Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574\u201381. https:\/\/doi.org\/10.1002\/cncr.29778.","journal-title":"Cancer"},{"key":"1335_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117569","volume":"180","author":"W Kaewlert","year":"2024","unstructured":"Kaewlert W, Sakonsinsiri C, Lert-Itthiporn W, Mahalapbutr P, Ali S, Rungrotmongkol T, et al. Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance. Biomed Pharmacother. 2024;180:117569. https:\/\/doi.org\/10.1016\/j.biopha.2024.117569.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1335_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167521","volume":"1871","author":"C Rattanasinchai","year":"2025","unstructured":"Rattanasinchai C, Navasumrit P, Chornkrathok C, Ruchirawat M. Kinase library screening identifies IGF-1R as an oncogenic vulnerability in intrahepatic cholangiocarcinoma stem-like cells. Biochim Biophys Acta Mol Basis Dis. 2025;1871(1):167521. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167521.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"8","key":"1335_CR55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/cncr.33364","volume":"127","author":"ES Tan","year":"2021","unstructured":"Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, et al. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 2021;127(8):1293\u2013300. https:\/\/doi.org\/10.1002\/cncr.33364.","journal-title":"Cancer"},{"issue":"13","key":"1335_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1917239.PMID:32955176;PMCID:PMC7571518","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383(13):207\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa1917239.PMID:32955176;PMCID:PMC7571518.","journal-title":"N Engl J Med"},{"issue":"25","key":"1335_CR57","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41(25):4097\u2013106. https:\/\/doi.org\/10.1200\/JCO.23.00434.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1335_CR58","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.ccell.2024.06.005","volume":"42","author":"AA Flores-G\u00f3mez","year":"2024","unstructured":"Flores-G\u00f3mez AA, Drosten M. Hrs-4642: the next piece of the puzzle to keep KRAS in check. Cancer Cell. 2024;42(7):1157\u20139. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"1335_CR59","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7067","volume":"23","author":"DA Deming","year":"2025","unstructured":"Deming DA. Development of KRAS inhibitors and their role for metastatic colorectal cancer. J Natl Compr Canc Netw. 2025;23(1):e247067. https:\/\/doi.org\/10.6004\/jnccn.2024.7067.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"1335_CR60","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 2020;10(8):1129\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0187.","journal-title":"Cancer Discov"},{"issue":"10","key":"1335_CR61","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/gutjnl-2023-331237","volume":"73","author":"FL Keggenhoff","year":"2024","unstructured":"Keggenhoff FL, Castven D, Becker D, Stojkovic S, Castven J, Zimpel C, et al. PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma. Gut. 2024;73(10):1712\u201324. https:\/\/doi.org\/10.1136\/gutjnl-2023-331237.","journal-title":"Gut"},{"issue":"2","key":"1335_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189267","volume":"1880","author":"AM Elsayed","year":"2025","unstructured":"Elsayed AM, Kittaneh M, Cebulla CM, Abdel-Rahman MH. An overview of BAP1 biological functions and current therapeutics. Biochimica et Biophysica Acta (BBA). 2025;1880(2):189267. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189267.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"2","key":"1335_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/1751-2980.13168","volume":"24","author":"XY Li","year":"2023","unstructured":"Li XY, Chen JQ, Aisa A, Ding YW, Zhang D, Yuan Y. Targeting BRCA-mutant biliary tract cancer: current evidence and future perspectives. J Dig Dis. 2023;24(2):85\u201397. https:\/\/doi.org\/10.1111\/1751-2980.13168.","journal-title":"J Dig Dis"},{"issue":"3","key":"1335_CR64","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.14874","volume":"29","author":"T Lerksuthirat","year":"2025","unstructured":"Lerksuthirat T, Prasopporn S, Wikiniyadhanee R, Chitphuk S, Stitchantrakul W, Owneium P, et al. DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. Oncol Lett. 2025;29(3):128. https:\/\/doi.org\/10.3892\/ol.2025.14874.","journal-title":"Oncol Lett"},{"key":"1335_CR65","doi-asserted-by":"publisher","unstructured":"Bourgeois W, Armstrong SA, Heikamp EB. Epigenetic Therapies. Cold Spring Harb Perspect Med 2024 Dec 18: a041637. https:\/\/doi.org\/10.1101\/cshperspect.a041637. Epub ahead of print. PMID: 39694694.","DOI":"10.1101\/cshperspect.a041637"},{"issue":"8","key":"1335_CR66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/oncolo\/oyae163","volume":"29","author":"A Mohan","year":"2024","unstructured":"Mohan A, Quingalahua E, Gunchick V, Paul S, Kumar-Sinha C, Crysler O, et al. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. Oncologist. 2024;29(8):725\u201330. https:\/\/doi.org\/10.1093\/oncolo\/oyae163.","journal-title":"Oncologist"},{"issue":"1","key":"1335_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00409-5","volume":"7","author":"K Zimmer","year":"2023","unstructured":"Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, et al. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ Precis Oncol. 2023;7(1):64. https:\/\/doi.org\/10.1038\/s41698-023-00409-5.","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"1335_CR68","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1335_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2024.2348852","author":"IA Voutsadakis","year":"2024","unstructured":"Voutsadakis IA. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies. Tissue Barriers. 2024. https:\/\/doi.org\/10.1080\/21688370.2024.2348852.","journal-title":"Tissue Barriers"},{"issue":"4","key":"1335_CR70","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/his.15407","volume":"86","author":"MN Kinzler","year":"2025","unstructured":"Kinzler MN, Gretser S, Schulze F, Bankov K, Abedin N, Bechstein WO, et al. Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre. Histopathology. 2025;86(4):640\u20136. https:\/\/doi.org\/10.1111\/his.15407.","journal-title":"Histopathology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01335-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T08:03:05Z","timestamp":1760860985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01335-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"13 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"207"}}